Floatz logo

Promethazine

Acute Lymphocytic Leukemia

PersonGen BioTherapeutics (Suzhou) Co., Ltd.Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Acute Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
SPANLECORTEMLOCEL
Novartis Pharmaceuticals
Phase 2BB
Basiliximab
City of Hope Medical Center
Phase 2BB
Lipitor
Loyola University
Phase 3BB
Allopurinol
Masonic Cancer Center, University of Minnesota
Phase 2B
18f-flt
University of Oklahoma
Phase 2B

View all 42 →

Same molecule, other indications

Promethazine is also rated in:

disruptive behavior disorderDormant
BB
Indicative ·
64 / 100
View asset →
migraine without auraDormant
B
Indicative ·
62 / 100
View asset →
physiological malfunction arising from mental factorDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →